What if regulators approve robotic pharmacists for retail pharmacies?
FDA clearance of autonomous dispensing robots threatens pharmacy-tech roles — a robotics-productivity and disinflationary-services read; long automation enablers, modest displacement drag. Rhymes with the May-2023 Nvidia capex-wave as the beneficiary template. Forward: pharmacy is already partly automated (script-filling robots exist), so the marginal displacement is incremental, not overnight — the 300k figure overstates near-term velocity given state board-of-pharmacy supervision rules.
Every number ships with its receipt — the odds, the range, the precedents, and a public grade at Reality Check. The statistical machinery that produces it is proprietary.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (electric blue) over time vs the market's (Polymarket, amber), from the past toward the 1–3 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. Loading the probability audit trail…
What it would mean
If this plays out, it is a risk-off shock. FDA clears autonomous dispensing robots for retail pharmacy, threatening 300,000 pharmacy-technician roles overnight. The trigger decomposes into signed root‑shocks — Job displacement ▲ · Robotics productivity ▲ — which propagate through our causal graph to the markets below.